Scientific Literature

Selected and regularly updated scholarly publications of original empirical and theoretical work on thalassaemia and sickle cell disease (SCD), divided according to subject.

Challenges of blood transfusions in β-thalassemia. Shah, F. T., Sayani, F., Trompeter, S., Drasar, E., & Piga, A. Blood reviews, 100588. (2019).

Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia. Aydinok Y, Piga A et al. British Journal of Haematology. (2019)

Red cell transfusion in paediatric patients with thalassaemia and sickle cell disease: Current status, challenges and perspectives.  Tzounakas V, Valsami S et al. Transfusion and Apheresis Science Journal. (2018)

Beta-thalassemia: renal complications and mechanisms: a narrative review. Demosthenous C, Vlachaki E, Apostolou C, et al. Hematology. 24:1;426-438. doi:10.1080/16078454.2019.1599096

Cumulative outcome of pre‐implantation genetic diagnosis for sickle cell disease: a 5‐year review. Vali, S., Mukhtar, S., et al. British Journal of Haematology. (2020)

Sickle Cell Pain Crisis: Clinical Guidelines for the Use of Oxygen. Omoigui, S. Practical Pain Management. (2020)

Mental stress causes vasoconstriction in subjects with sickle cell disease and in normal controls. Shah P., Khaleel M. et al. Haematologica 105.1 (2020): 83-90.

Sickle Cell Trait. D. Ashorobi, R. Bhatt. Treasure Island (FL): StatPearls Publishing. (2020)

Web-Based Technology to Improve Disease Knowledge Among Adolescents With Sickle Cell Disease: Pilot Study. Saulsberry A. C., Hodges J. R., Cole A., Porter J. S., & Hankins J. JMIR Pediatrics and Parenting3(1), e15093. (2020)

Understanding the Complications of Sickle Cell Disease. Tanabe P., et al. AJN The American Journal of Nursing 119.6 (2019): 26-35.

Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe. Maitra P., Caughey M., Robinson L. et al. Haematologica. (2019)

Current challenges in the management of patients with sickle cell disease–A report of the Italian experience. Russo G., De Franceschi L., Colombatti, et al. Orphanet journal of rare diseases14(1). (2019).

New therapeutic options for the treatment of sickle cell disease. Matte  A., Zorzi F., Mazzi F., Federti E. et al. Mediterranean journal of hematology and infectious diseases11(1). (2019)

The carrier state for sickle cell disease is not completely harmless.  Xu, J.Z. and Thein, S.L.  Haematologica104(6). (2019)

Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent. Rigano P., De Franceschi L., Piga A. et al. Blood Cells, Molecules, and Diseases. (2018)

Newborn screening for sickle cell disease in Europe: recommendations from a Pan‐European Consensus Conference. Lobitz S., Telfer P., Angastiniotis M., et al.  British journal of haematology183(4). (2018)

Review of Medication Therapy for the Prevention of Sickle Cell Crisis. Riley, T.R., Boss, A., McClain, D. and Riley, T.T.Pharmacy and Therapeutics43(7). (2018)

Sickle cell screening in Europe: the time has come. Shook, L.M. and Ware, R.E. British journal of haematology183(4). (2018).

Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Gluckman E., Cappelli B., et al. Blood129(11). (2017).

How we manage iron overload in sickle cell patients. Coates T.D. and Wood J.C.  British journal of Haematology177(5). (2017).

Back to top button